Komori
Governance4574TAIKO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice Regarding the Application to Change the Market Segment to the Tokyo Stock Exchange Standard Market

The Board of Directors resolved to apply to change the Company's market segment from the Tokyo Stock Exchange Prime Market to the Standard Market. The market segment has not been changed at this time; the Company is currently at the application stage.

Worth reading
80Important
Scored from 1 of 5 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Contents of this filing

Changes this time

At a meeting of the Board of Directors held on 25 August 2026, the Company resolved to apply to change its market segment to the Tokyo Stock Exchange Standard Market.

この書類は、機関設計や取締役会の構成そのものは述べていません。上に示したのは、この書類が述べている変更点です。

Contents of this filing
ItemDetails
Changes this timeAt a meeting of the Board of Directors held on 25 August 2026, the Company resolved to apply to change its market segment to the Tokyo Stock Exchange Standard Market.
Items this document does not state (7)
Corporate Governance StructureNumber of directorsNumber of independent officersCommitteePolicy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

In light of the Company's current scale, business environment and future growth strategy, it determined that it was necessary to consider the ongoing efforts required to comply with the Prime Market's continued listing criteria and the allocation of management resources from the perspective of its long-term management strategy and maximizing shareholder value. The Company determined that the Standard Market is better suited to its current business scale and stage of growth, and that sustainable growth and the enhancement of corporate value over the medium to long term would serve the interests of its stakeholders.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Application to Change the Market Segment to the Tokyo Stock Exchange Standard Market | TAIKO PHARMACEUTICAL CO.,LTD. (4574) timely disclosure | Komori